{"id":"statin-plus-fenofibrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia or muscle pain"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Rhabdomyolysis (rare)"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Fenofibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), which upregulates lipoprotein lipase and reduces hepatic triglyceride production. The combination addresses multiple dyslipidemia patterns, particularly in patients with elevated triglycerides and low HDL cholesterol alongside elevated LDL cholesterol.","oneSentence":"This combination reduces cholesterol and triglycerides through dual lipid-lowering pathways: statins inhibit HMG-CoA reductase to lower LDL cholesterol, while fenofibrate activates PPAR-alpha to reduce triglycerides and raise HDL cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:41.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with elevated LDL cholesterol and triglycerides"},{"name":"Cardiovascular risk reduction in patients with mixed dyslipidemia"}]},"trialDetails":[{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":"Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder","enrollment":59},{"nctId":"NCT06293417","phase":"NA","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-03-01","conditions":"T2DM (Type 2 Diabetes Mellitus), Dyslipidemias","enrollment":3958},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00726856","phase":"","title":"Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Dyslipidemia","enrollment":1200},{"nctId":"NCT04650152","phase":"","title":"Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)","status":"COMPLETED","sponsor":"Abbott","startDate":"2020-10-27","conditions":"Hypertriglyceridemia, Metabolic Syndrome","enrollment":1000},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT02890992","phase":"PHASE2","title":"An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-15","conditions":"Hypercholesterolaemia","enrollment":42},{"nctId":"NCT02232360","phase":"PHASE4","title":"Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2014-01","conditions":"Coronary Artery Disease","enrollment":106},{"nctId":"NCT03874260","phase":"PHASE4","title":"Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy","status":"UNKNOWN","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2018-07-25","conditions":"Dyslipidemias","enrollment":180},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT02069717","phase":"","title":"Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)","status":"WITHDRAWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2013-10","conditions":"Metabolic Syndrome","enrollment":""},{"nctId":"NCT01025492","phase":"PHASE4","title":"Study of Trilipix Effects on Lipids and Arteries","status":"TERMINATED","sponsor":"University of Utah","startDate":"2009-11","conditions":"Dyslipidemia","enrollment":24},{"nctId":"NCT01462877","phase":"PHASE4","title":"A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic","status":"COMPLETED","sponsor":"Abbott","startDate":"2011-10","conditions":"Dyslipidemias, Cardiovascular Diseases, Hypertriglyceridemia","enrollment":506},{"nctId":"NCT02314533","phase":"PHASE4","title":"Evaluate the Efficacy of Fenofibrate on Microalbuminuria","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2014-12","conditions":"Microalbuminuria","enrollment":200},{"nctId":"NCT01211847","phase":"PHASE2","title":"Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":44},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT00362323","phase":"PHASE3","title":"Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-10","conditions":"Dyslipidemia/Glucose Metabolism Disorder","enrollment":482},{"nctId":"NCT00300430","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-09","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":1911},{"nctId":"NCT00261352","phase":"PHASE3","title":"GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2005-03","conditions":"Type 2 Diabetes","enrollment":1000},{"nctId":"NCT00309712","phase":"NA","title":"Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2002-08","conditions":"Type II Diabetes Mellitus, Mixed Dyslipidemia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Statin plus fenofibrate","genericName":"Statin plus fenofibrate","companyName":"University of Ioannina","companyId":"university-of-ioannina","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces cholesterol and triglycerides through dual lipid-lowering pathways: statins inhibit HMG-CoA reductase to lower LDL cholesterol, while fenofibrate activates PPAR-alpha to reduce triglycerides and raise HDL cholesterol. Used for Dyslipidemia with elevated LDL cholesterol and triglycerides, Cardiovascular risk reduction in patients with mixed dyslipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}